(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 142 283**
A2

(12) # EUROPEAN PATENT APPLICATION

(21) Application number: 84307102.8

(22) Date of filing: 17.10.84

(51) Int. Cl.⁴: C 07 C 91/30
C 07 C 91/32, C 07 D 215/22
C 07 C 149/24, C 07 C 127/19
C 07 C 103/82, C 07 C 103/50
C 07 C 103/42, C 07 C 147/02
C 07 C 143/75, C 07 C 91/44
//C07C43/23, C07C43/174,
C07C121/75, C07C93/14,
C07C149/273, C07D263/14,
C07D317/28, C07C65/03,
C07C149/40, C07C69/157,
C07C69/612, C07C79/36,
C07C47/575, C07C103/76,
C07C103/78, C07C103/737,
C07C103/38, C07C103/60,
C07C103/58

(30) Priority: 25.10.83 GB 8328489
25.10.83 GB 8328490
06.12.83 GB 8332447
06.12.83 GB 8332448
06.12.83 GB 8332452
24.01.84 GB 8401746
24.01.84 GB 8401747
24.01.84 GB 8401748
24.01.84 GB 8401750

(43) Date of publication of application:
22.05.85 Bulletin 85/21

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: FISONS plc
Fison House Princes Street
Ipswich Suffolk IP1 1QH(GB)

(72) Inventor: Dixon, John
Church Farmhouse Great Dalby
Nr Melton Mowbray Leicestershire(GB)

(72) Inventor: Ince, Francis
78 Leconfield Road
Loughborough Leicestershire(GB)

(72) Inventor: Tinker, Alan Charles
97 Knightthorpe Road
Loughborough Leicestershire(GB)

(74) Representative: Craig, Christopher Bradberry et al,
Fisons plc 12 Derby Road
Loughborough Leicestershire LE11 0BB(GB)

(54) **Phenylethylamines, process for their preparation and compositions containing them.**

(57) There are described compounds of formula I,



in which R_1 represents OH, $NR_{11}R_{12}$, CH_2R_{12} or fluorine,

R_2, R_3, R_{11}, R_{12} and R_{20} have various meanings as defined herein for example R_2 and R_3 may represent hydrogen, halogen, alkyl C1 to 6 or nitro;

W represents a single bond, a disubstituted benzene or a 1,4-cyclohexanediyl group,

X represents NH, O, S, SO_2, CO, CH_2, CONH or -COO;

Y, amongst other meanings defined herein, represents $(CH_2)_q$, CO, CS and SO_2,

./...

EP 0 142 283 A2

Z represents a single bond, NR_{16}, CH_2, O, CO, S or SO_2, in which R_{16} represents hydrogen or alkyl C1 to 6,

n and m each independently represent an integer from 1 to 4 inclusive,

q represents an integer from 1 to 3 inclusive,

p represents 0 or an integer from 1 to 3 inclusive,

R_{15} represents hydrogen or chlorine,

R_{20}, amongst other meanings defined herein may represent hydrogen,

with four provises as defined herein, and pharmaceutically acceptable derivatives thereof.

There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

q preferably represents 1 or 2.

p preferably represents 0, 1 or 2.

When Z represents a single bond, we prefer the sum of n+m to be from 5 to 7 inclusive, especially 6.

The compounds of formula I, and pharmaceutically acceptable derivatives thereof, are useful because they possess pharmacological activity in animals. Thus the compounds act on peripheral and/or central dopamine receptors. As such, they lower blood pressure, reduce heart rate and increase blood flow to certain vascular beds, e.g. renal beds. Some compounds also have an action on other adrenoreceptors, and these exhibit cardiac stimulant and bronchodilator effects. Activity of the compounds has been observed in the following assay systems:

(a) canine renal blood flow, McNay and Goldberg, J. Pharmac, Exp. Ther., 151, 23-31, 1966.

(b) rabbit isolated ear artery, McCullogh, Rand and Story, Br. J. Pharmac, 49, 141-142, 1973, and

(c) cat nictitating membrane, Gyorgy and Doda, Arch. Int. Pharmacodyn, 226, 194-206, 1977.

The compounds of the invention are indicated for use in the treatment of congestive heart failure, renal failure, angina pectoris, ischaemic heart disease, hypertension and reversible obstructive airways disease, hyperprolactinaemia and also in Parkinson's disease and

other neurological disorders. Compounds of the invention are also indicated for use in the treatment of glaucoma, gastric hypersecretion, e.g. in peptic ulcers, premature labour, acromegaly, and improvement of the blood supply to and healing of intestinal anastomoses and stomata.

The dosage administered will naturally depend on the compound employed, the mode of administration and the desired effect. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of from 0.05 µg to 50mg per kilogram of body weight per day. For man, the indicated total daily dosage is in the range 2.5 µg to 3.5g, which may be administered in divided doses of, for example 1 µg to 750mg.

The new compounds of the present invention may be used in combination with, or sequentially with, a wide variety of other pharmaceutically active substances. Where appropriate the compounds may be mixed with one or more other active substances. The particular mixture or dose regimen used, and ratio of the active ingredients will depend on a variety of factors including the condition to be treated, the mode of administration, the particular active ingredients and the patient concerned.

Examples of compounds with which the present compounds may be mixed include:

beta-blockers, especially cardioselective beta

What we claim is:

1. A compound of formula I,



I

in which R_1 represents OH, $NR_{11}R_{21}$, CH_2R_{12}, or fluorine,

when R_1 represents OH, CH_2R_{12} or fluorine,

R_2 and R_3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitro, nitrile, $(CH_2)_pR_9$ or SR_9,

when R_1 represents $NR_{11}R_{21}$, R_{11} represents hydrogen, CHO, COR_{13}, $COOR_{13}$, $CONH_2$, SO_2R_{13}, CH_2R_{14} or alkyl C1 to 6 and R_{21} represents hydrogen and R_2 and R_3 are as defined above, or

R_{11} and R_2 together form the chain $= CR_{23}-CH=CH-$ in which the carbon bearing R_{23} is adjacent to the nitrogen, R_{23} represents hydrogen or hydroxy, R_3 is as defined above and R_{21} has no meaning, or

R_{11} and R_2 together form the chain $-COCH_2-$ in which -CO- is adjacent to the nitrogen, R_3 is as defined above and R_{21} represents hydrogen, or

R_{11} and R_2 together represent 1,2-phenylene, R_3

is as defined above, and R_{21} represents hydrogen,

R_{12} represents hydrogen, OH, SO_2R_{13} or alkyl C1 to 6,

R_{13} represents alkyl C1 to 6,

R_{14} represents phenyl or alkoxy C1 to 6 phenyl,

W represents a single bond, a 1,2; 1,3; or 1,4-disubstituted benzene ring; a -CH=CH-group or a 1,4-cyclohexanediyl group;

X represents NH, O, S, SO_2, CO, CH_2, CONH or -COO;

Y represents $(CH_2)q$, CO, CS, SO_2 and R_{20} represents hydrogen, or Y represents $CR_{15}R_{16}CR_{17}R_{18}$, wherein the carbon atom bearing R_{15} and R_{16} is adjacent to X and in which

R_{17} and R_{18}, together with the carbon atom to which they are attached form a carbonyl group, and R_{15}, R_{16} and R_{20} each represent hydrogen, or

R_{15} and R_{20} together form a chain $-CH_2-$, and R_{16}, R_{17} and R_{18} each represent hydrogen, or

R_{15}, R_{16}, R_{17} and R_{18} each independently represent hydrogen or alkyl C1 to 6 and R_{20} represents hydrogen;

Z represents a single bond, NR_{19}, CH_2, O, CO, S or SO_2,

in which R_{19} represents hydrogen or alkyl C1 to 6;

n, and m each independently represent an integer from

1 to 4 inclusive;

q represents an integer from 1 to 3 inclusive;

p represents 0 or an integer from 1 to 3 inclusive;

R_9 represents phenyl or phenyl substituted by hydroxy, and

R_{10} represents hydrogen or chlorine,

provided that

i) when R_1 represents -OH, R_2 and R_3 both represent hydrogen,

X represents NH, Y represents $(CH_2)_q$, Z represents a single bond and R_{20} represents hydrogen,

W does not represent a single bond;

ii) when R_1 represents -OH, R_2 and R_3 both represent hydrogen, W represents a single bond,

X represents NH and Z represents a single bond, then at least one of R_{15}, R_{16}, R_{17} and R_{18} is alkyl C1 to 6;

iii) when X represents SO_2, CO, COOO or CONH, Y does not represent CO, CS or SO_2;

iv) when Y represents CO, CS or SO_2, then Z does not represent CO or SO_2,

and pharmaceutically acceptable derivatives thereof.

2. A compound according to Claim 1 for use as a pharmaceutical.

3. A compound according to Claim 1 or 2, wherein

R_1 represents OH or fluorine,

R_2 and R_3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitrile, phenyl, $(CH_2)_pR_9$ or SR_9.

4. A compound according to Claim 1 or 2, wherein

R_1 represents $NR_{11}R_{21}$ or CH_2R_{12},

either R_2 represents hydrogen, R_{11} represents hydrogen, CHO, COR_{13}, $COOR_{13}$, $CONH_2$, SO_2R_{13}, CH_2R_{14} or alkyl C1 to 6 and R_{21} represents hydrogen, or

R_2 and R_{11} together form the chain $=CR_{23}-CH=CH-$, in which the carbon bearing R_{23} is adjacent to the nitrogen, R_{23} represents hydrogen or hydroxy, and R_{21} has no meaning, or

R_2 and R_{11} together form the chain $-COCH_2-$ in which -CO- is adjacent to the nitrogen, and R_{21} represents hydrogen, or

R_2 and R_{11} together represent 1,2-phenylene, and R_{21} represents hydrogen,

R_3 and R_{20} each represent hydrogen,

W and Z each represent a single bond,

X represents NH, and

Y represents $(CH_2)_q$.

5. A compound according to any one of Claim 1, 2 or 3, wherein

R_1 represents OH,

R_2 and R_3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitrile, phenyl $(CH_2)_pR_9$ or SR_9,

W and Z each represent a single bond,

X represents NH,

Y represents $(CH_2)_q$, and

R_{20} represents hydrogen.

6. 3-Chloro-4-[2-(6-(2-phenylethylamino)hexylamino) ethyl]-1,2-benzenediol;

3-[2-Phenylethyl]-4-[2-[6-[2-phenylethylamino] hexylamino]ethyl]-1,2-benzenediol;

3-Ethyl-4-[2-[6-[2-phenylethylamino]hexylamino] -ethyl]-1,2-benzenediol;

3-Bromo-4-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

or a pharmaceutically acceptable salt thereof.

7. 2-Hydroxy-5[2-(6-(2-phenylethylamino)hexylamino)ethyl] benzene methanol;

N-[2-hydroxy-5-[2-[6-(2-phenylethylamino)hexylamino] ethyl]phenyl]methanesulphonamide;

or a pharmaceutically acceptable salt thereof.

8. 5-[2-(6-(2-Phenylethylamino)hexylamino)ethyl]-3-propyl-1,2-benzenediol;

4-[2-(6-(2-Phenylethylamino)hexylamino)ethyl]3-propyl-1,2-benzenediol;

3-Methyl-4-[2-(6-(2-phenylethylamino)hexylamino)ethyl]-1,2-benzenediol;

3-Nitro-4-[2-(6-(2-phenylethylamino)hexylamino)ethyl]-1,2-benzenediol;

3-Nitro-5-(2-(6-(2-phenylethylamino)hexylamino)ethyl]-1,2-benzenediol;

3-Ethyl-4-[2-[6-[2-phenylethylamino]hexylamino]-ethyl]-1,2-benzenediol;

3-Butyl-4-[2-[6-[2-phenylethylamino]hexylamino]-ethyl]-1,2-benzenediol;

6-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-[1,1'-biphenyl]-2,3-diol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-1,2,3-benzenetriol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]--3-phenylmethyl-1,2-benzenediol;

3-Butyl-4-[2-[6-[2-phenylethylamino]hexylamino]-ethyl]-1,2-benzenediol;

5-Fluoro-4-[2-[6-[2-phenylethylamino]hexylamino]-ethyl]-1,2-benzenediol;

5-Methyl-4-[2-[6-[2-phenylethylamino]hexylamino]

ethyl]-1,2-benzenediol;

3-Fluoro-5-[2-[6-[2-phenylethylamino]hexylamino]ethyl]-1,2-benzenediol;

3-Methyl-5-[2-[6-2-phenylethylamino]hexylamino]ethyl]-1,2-benzenediol;

6-Fluoro-4-[2-[6-[2-phenylethylamino]hexylamino]ethyl]-3-propyl-1,2-benzenediol;

3-[1-Methylethyl]-4-[2-[6-[2-phenylethylamino]-hexylamino]ethyl]-1,2-benzenediol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-3-phenylthio-1,2-benzenediol;

6-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-[1,1'-biphenyl]-2,3,4'-triol;

3-Chloro-5-[2-[6-[2-phenylethylamino]hexylamino]ethyl]-1,2-benzenediol;

3-Bromo-5-[2-[6-[2-phenylethylamino]hexylamino]ethyl]-1,2-benzenediol;

4-[2-[4-[(2-Phenylethyl)aminomethyl]phenylmethylamino]ethyl]1,2-benzenediol;

4-[2-[4-[(2-Phenylethyl)aminomethyl]-trans cyclohexylmethylamino]ethyl]-1,2-benzenediol;

4-[2-[2-[2-[2-(2-Phenylethyl)aminoethyl]phenyl]-ethyl]aminoethyl]-1,2-benzenediol;

4-[2-[3-[2-[2-(2-Phenylethylaminomethyl)phenyl]propyl amino]ethyl]-1,2-benzenediol;

E-4-[2-[6-(2-Phenylethylamino)-hex-3-enylamino]ethyl]-1,2-benzenediol;

4-[2-(9-Phenylnonylamino)ethyl]-1,2-benzenediol;

4-[2-[6-(2-Phenylethylthio)hexylamino)ethyl]-1,2 benzenediol;

4-[2-[6-[2-Phenylethoxy]hexylamino]ethyl-1,2-benzenediol;

N-6-[2-(3,4-Dihydroxyphenyl)ethylamino]hexyl-N'-phenylurea

N-[6-[2-(3,4-Dihydroxyphenyl)ethylamino]hexyl]benzene acetamide;

4-[2-[6-(2,3-Dihydro-IH-inden-2-ylamino)hexylamino] ethyl]-1,2-benzenediol;

4-[2-[6-(2-Methyl-2-phenylpropylamino)hexylamino]_ ethyl]-1,2-benzenediol;

4-[2-[6-(1,1-dimethyl-2-phenyl ethylamino)hexylamino] ethyl]-1,2-benzenediol;

4-[2-(6-[2-(Phenylamino)ethylamino]hexylamino]ethyl]-1,2-benzenediol;

4-[2-[6-(2-Phenyloxyethylamino)hexylamino]ethyl]-1,2-benzenediol;

4-[2-[6-[2-(Phenylthio)ethylamino]hexylamino]ethyl-1,2-benzenediol;

6-[2-(3,4-Dihydroxyphenyl)ethylamino]-N-(2-phenylethyl)hexanamide;

2-Phenylethyl 6-[2-(3,4-dihydroxyphenyl)ethylamino]-hexanoate;

2-Methylsulphonylmethyl-5-[2-(6-(2-phenylethylamino) hexylamino)ethyl]phenol;

2-Amino-4-[2-[6-(2-phenylethylamino)hexylamino] ethyl]phenol;

2-(Methylamino)-4-[2-[6-(2-phenylethylamino)hexyl amino]ethyl]phenol;

4-[2-[6-(2-Phenylethylamino)hexylamino]ethyl]-2-(phenylmethylamino)phenol;

N-[2-Hydroxy-5-[2-[6-(2-phenylethylamino)-hexylamino]ethyl]phenyl]acetamide;

2-Fluoro-4-[2-[6-(2-phenylethylamino)hexylamino]ethyl] phenol;

1,2-Dihydro-8-hydroxy-5-[2-[6-(2-phenylethylamino)-hexylamino]ethyl]-2-oxo-2H-quinoline;

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition according to any one of the preceding Claims in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. A process for the production of a compound of formula I according to Claim 1, or a pharmaceutically acceptable derivative thereof, which comprises removal of at least one protecting group from a compound of formula II,



II

in which R_3, R_{10}, R_{20} n, m, W and Y are as defined in Claim 1,

R_4a and R_5a, which may be the same or different, each represent hydrogen or a protecting group,

R_1a, R_2a, Xa and Za have the same respective meanings as R_1, R_2, X and Z defined in Claim 1, save that in addition

R_1a represents OR_6a, $NR_{11}aR_{21}a$ or CH_2OR_7a, in which R_6a, R_7a and one or both of $R_{11}a$ and $R_{21}a$ may represent a protecting group, $R_{11}a$ and $R_{21}a$ otherwise being defined as R_{11} and R_{21} in Claim 1, respectively;

Xa may represent NR_8a, in which R_8a represents a protecting group,

Za may represent $NR_{19}a$, in which $R_{19}a$ has the same meaning as R_{19} defined above, save that in addition, $R_{19}a$ may represent a protecting group,

provided that the compound of formula II bears at least one protecting group,

and where desired or necessary converting the

resulting compound of formula I to a pharmaceutically acceptable derivative thereof, or vice versa.

What we claim is:

1. A process for the production of a compound of formula I,



I

in which R_1 represents OH, $NR_{11}R_{21}$, CH_2R_{12}, or fluorine,

when R_1 represents OH, CH_2R_{12} or fluorine,

R_2 and R_3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitro, nitrile, $(CH_2)_pR_9$ or SR_9;

when R_1 represents $NR_{11}R_{21}$, R_{11} represents hydrogen, CHO, COR_{13}, $COOR_{13}$, $CONH_2$, SO_2R_{13}, CH_2R_{14} or alkyl C1 to 6 and R_{21} represents hydrogen and R_2 and R_3 are as defined above, or

R_{11} and R_2 together form the chain $= CR_{23}-CH=CH-$ in which the carbon bearing R_{23} is adjacent to the nitrogen, R_{23} represents hydrogen or hydroxy, R_3 is as defined above and R_{21} has no meaning, or

R_{11} and R_2 together form the chain $-COCH_2-$ in which -CO- is adjacent to the nitrogen, R_3 is as defined above and R_{21} represents hydrogen, or

R_{11} and R_2 together represent 1,2-phenylene, R_3 is as defined above, and R_{21} represents hydrogen,

R_{12} represents hydrogen, OH, SO_2R_{13} or alkyl C1 to 6,

R_{13} represents alkyl C1 to 6,

R_{14} represents phenyl or alkoxy C1 to 6 phenyl,

W represents a single bond, a 1,2; 1,3; or 1,4-disubstituted benzene ring; a -CH=CH-group or a 1,4-cyclohexanediyl group;

X represents NH, O, S, SO_2, CO, CH_2, CONH or -COO;

Y represents $(CH_2)q$, CO, CS, SO_2 and R_{20} represents hydrogen, or Y represents $CR_{15}R_{16}CR_{17}R_{18}$, wherein the carbon atom bearing R_{15} and R_{16} is adjacent to X and in which

R_{17} and R_{18}, together with the carbon atom to which they are attached form a carbonyl group, and R_{15}, R_{16} and R_{20} each represent hydrogen, or

R_{15} and R_{20} together form a chain $-CH_2-$, and R_{16}, R_{17} and R_{18} each represent hydrogen, or

R_{15}, R_{16}, R_{17} and R_{18} each independently represent hydrogen or alkyl C1 to 6 and R_{20} represents hydrogen;

Z represents a single bond, NR_{19}, CH_2, O, CO, S or SO_2,

in which R_{19} represents hydrogen or alkyl C1 to 6;

n, and m each independently represent an integer from 1 to 4 inclusive;

q represents an integer from 1 to 3 inclusive;

p represents 0 or an integer from 1 to 3 inclusive;

R_9 represents phenyl or phenyl substituted by hydroxy, and

R_{10} represents hydrogen or chlorine,

provided that

i) when R_1 represents -OH, R_2 and R_3 both represent hydrogen,

X represents NH, Y represents $(CH_2)_q$, Z represents a single bond and R_{20} represents hydrogen,

W does not represent a single bond;

ii) when R_1 represents -OH, R_2 and R_3 both represent hydrogen, W represents a single bond;

X represents NH and Z represents a single bond, then at least one of R_{15}, R_{16}, R_{17} and R_{18} is alkyl C1 to 6;

iii) when X represents SO_2, CO, COO or CONH, Y does not represent CO, CS or SO_2;

iv) when Y represents CO, CS or SO_2, then Z does not represent CO or SO_2,

and pharmaceutically acceptable derivatives thereof,

which comprises removal of at least one protecting group from a compound of formula II,



II

in which R_3, R_{10}, R_{20} n, m, W and Y are as defined above,

R_4a and R_5a, which may be the same or different, each represent hydrogen or a protecting group,

R_1a, R_2a, Xa and Za have the same respective meanings as R_1, R_2, X and Z defined above, save that in addition

R_1a represents OR_6a, $NR_{11}aR_{21}a$ or CH_2OR_7a, in which R_6a, R_7a and one or both of $R_{11}a$ and $R_{21}a$ may represent a protecting group, $R_{11}a$ and $R_{21}a$ otherwise being defined as R_{11} and R_{21} above, respectively;

Xa may represent NR_8a, in which R_8a represents a protecting group,

Za may represent $NR_{19}a$, in which $R_{19}a$ has the same meaning as R_{19} defined above, save that in addition, $R_{19}a$ may represent a protecting group,

provided that the compound of formula II bears at least one protecting group,

and where desired or necessary converting the resulting compound of formula I to a pharmaceutically

acceptable derivative thereof, or vice versa.

2. A process according to Claim 1, wherein

R_1 represents OH or fluorine,

R_2 and R_3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitrile, phenyl, $(CH_2)_pR_9$ or SR_9.

3. A process according to Claim 1, wherein

R_1 represents $NR_{11}R_{21}$ or CH_2R_{12},

either R_2 represents hydrogen, R_{11} represents hydrogen, CHO, COR_{13}, $COOR_{13}$, $CONH_2$, SO_2R_{13}, CH_2R_{14} or alkyl C1 to 6 and R_{21} represents hydrogen, or

R_2 and R_{11} together form the chain $=CR_{23}-CH=CH-$, in which the carbon bearing R_{23} is adjacent to the nitrogen, R_{23} represents hydrogen or hydroxy, and R_{21} has no meaning, or

R_2 and R_{11} together form the chain $-COCH_2-$ in which -CO- is adjacent to the nitrogen, and R_{21} represents hydrogen, or

R_2 and R_{11} together represent 1,2-phenylene, and R_{21} represents hydrogen,

R_3 and R_{20} each represent hydrogen,

W and Z each represent a single bond,

X represents NH,

Y represents $(CH_2)_q$.

4. A process according to Claim 1, wherein the compound of formula I is

3-Chloro-4-[2-(6-(2-phenylethylamino)hexylamino) ethyl]-1,2-benzenediol;

3-[2-Phenylethyl]-4-[2-[6-[2-phenylethylamino] hexylamino]ethyl]-1,2-benzenediol;

3-[2-[4-Hydroxyphenyl]ethyl]-4-[2-[6-[2-phenyl ethylamino]hexylamino]ethyl]-1,2-benzenediol;

3-Bromo-4-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

or a pharmaceutically acceptable salt thereof.

6. A process according to Claim 1, wherein the compound of formula I is

2-Hydroxy-5[2-(6-(2-phenylethylamino)hexylamino)ethyl] benzene methanol;

N-[2-hydroxy-5-[2-[6-(2-phenylethylamino)hexylamino] ethyl]phenyl]methanesulphonamide;

or a pharmaceutically acceptable salt thereof.

7. A process according to Claim 1, wherein the compound of formula I is

5-[2-(6-(2-Phenylethylamino)hexylamino)ethyl]-3-propyl-1,2-benzenediol;

4-[2-(6-(2-Phenylethylamino)hexylamino)ethyl]3-propyl-1,2-benzenediol;

3-Methyl-4-[2-(6-(2-phenylethylamino)hexylamino) ethyl]-1,2-benzenediol;

3-Nitro-4-[2-(6-(2-phenylethylamino)hexylamino) ethyl]-1,2-benzenediol;

3-Nitro-5-(2-(6-(2-phenylethylamino)hexylamino) ethyl]-1,2-benzenediol;

3-Ethyl-4-[2-[6-[2-phenylethylamino]hexylamino] -ethyl]-1,2-benzenediol;

3-Butyl-4-[2-[6-[2-phenylethylamino]hexylamino]- ethyl]-1,2-benzenediol;

6-[2-[6-[2-Phenylethylamino]hexylamino]ethyl] -[1,1'-biphenyl]-2,3-diol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]- 1,2,3-benzenetriol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]- -3-phenylmethyl-1,2-benzenediol;

3-Fluoro-4-[2-[6-[2-phenylethylamino]hexylamino]- ethyl]-1,2-benzenediol;

5-Fluoro-4-[2-[6-[2-phenylethylamino]hexylamino] -ethyl]-1,2-benzenediol dihydrobromide; mp 218-220°;

5-Methyl-4-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

3-Fluoro-5-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

3-Methyl-5-[2-[6-2-phenylethylamino]hexylamino]

ethyl]-1,2-benzenediol;

6-Fluoro-4-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-3-propyl-1,2-benzenediol;

3-[1-Methylethyl]-4-[2-[6-[2-phenylethylamino]-hexylamino]ethyl]-1,2-benzendiol;

4-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-3-phenylthio-1,2-benzenediol;

6-[2-[6-[2-Phenylethylamino]hexylamino]ethyl]-[1,1'-biphenyl]-2,3,4'-triol;

3-Chloro-5-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

3-Bromo-5-[2-[6-[2-phenylethylamino]hexylamino] ethyl]-1,2-benzenediol;

4-[2-[4-[(2-Phenylethyl)aminomethyl]phenylmethylamino] ethyl]1,2-benzenediol;

4-[2-[4-[(2-Phenylethyl)aminomethyl]-trans cyclohexylmethylamino]ethyl]-1,2-benzenediol;

4-[2-[2-[2-[2-(2-Phenylethyl)aminoethyl]phenyl]-ethyl]amino-ethyl]-1,2-benzenediol;

4-[2-[3-[2-[2-(2-Phenylethylaminomethyl)phenyl]propyl amino]ethyl]-1,2-benzenediol;

E-4-[2-[6-(2-Phenylethylamino)-hex-3-enylamino]ethyl] -1,2-benzenediol;

4-[2-(9-Phenylnonylamino)ethyl]-1,2-benzenediol;

4-[2-[6-(2-Phenylethylthio)hexylamino)ethyl]-1,2

benzenediol;

4-[2-[6-[2-Phenylethoxy]hexylamino]ethyl-1,2-benzenediol;

N-6-[2-(3,4-Dihydroxyphenyl)ethylamino]hexyl-N'-phenylurea;

N-[6-[2-(3,4-Dihydroxyphenyl)ethylamino]hexyl]benzene acetamide;

4-[2-[6-(2,3-Dihydro-IH-inden-2-ylamino)hexylamino] ethyl]-1,2-benzenediol;

4-[2-[6-(2-Methyl-2-phenylpropylamino)hexylamino]-ethyl]-1,2-benzenediol;

4-[2-[6-(1,1-dimethyl-2-phenyl ethylamino)hexylamino] ethyl]-1,2-benzenediol ;

4-[2-(6-[2-(Phenylamino)ethylamino]hexylamino]ethyl]-1,2-benzenediol;

4-[2-[6-(2-Phenyloxyethylamino)hexylamino]ethyl]-1,2-benzenediol;

4-[2-[6-[2-(Phenylthio)ethylamino]hexylamino]ethyl-1,2-benzenediol;

6-[2-(3,4-Dihydroxyphenyl)ethylamino]-N-(2-phenylethyl)hexanamide;

2-Phenylethyl 6-[2-(3,4-dihydroxyphenyl)ethylamino]-hexanoate;

2-Methylsulphonylmethyl-5-[2-(6-(2-phenylethylamino) hexylamino)ethyl]phenol;

2-Amino-4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]-phenol;

2-(Methylamino)-4-[2-[6-(2-phenylethylamino)hexyl amino]ethyl]phenol;

4-[2-[6-(2-Phenylethylamino)hexylamino]ethyl]-2-(phenylmethylamino)phenol;

N-[2-Hydroxy-5-[2-[6-(2-phenylethylamino)hexylamino]-ethyl]phenyl]acetamide;

2-Fluoro-4-[2-[6-(2-phenylethylamino)hexylamino]ethyl] phenol;

1,2-Dihydro-8-hydroxy-5-[2-[6-(2-phenylethylamino) hexylamino]ethyl]-2-oxo-2H-quinoline,

or a pharmaceutically acceptable salt thereof.